Emfret presents novel anticoagulant
German biotech spin-out Emfret Analytics GmbH & Co. KG has presented a first in class anticoagulant that helps preventing heart attacks and stroke while showing less adverse effects than approved meds.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1148 entries already.
Entries by Thomas Gabrielczyk
BioNTech: ADC study continues with conditions
/in News/by Thomas GabrielczykGood news for BioNTech SE: The safety study of the ADC BNT326/YL202 developed by MediLink Therapeutics, which was suspended by the FDA in mid-June, will continue.
Bavarian Nordic A/S applies for EU label extension of mpox vaccine
/in News/by Thomas GabrielczykDanish vaccine maker Bavarian Nordic A/S has submitted data to the EMA that support label extension of its mpox vaccine imvanex indication to include adolescents 12 to 17 years of age.
Evotec axes 400 jobs worldwide
/in News/by Thomas GabrielczykAfter the drug discovery specialist Evotec SE lowered its annual forecast and lost almost 75% of its market capitalisation in just eight months, the new CEO, Christian Wojczewski, is taking action and closing non-profitable areas.
Nitrogenases also can fix CO2
/in News/by Thomas GabrielczykInvestigating substrate selectivity of nitrogenase enzymes in phototrophic R. capsulatus bacteria, German microbiologist have found one converting CO2 to formiate and methane opening the way to fossil oil-free hydrocarbon synthesis
Sphingotec secures Series C financing
/in News/by Thomas GabrielczykGerman diagnostics specialist SphingoTec GmbH has closed a €5m Series C financing round led by Think.Health Ventures.
New antibiotic breaks resistance
/in News/by Thomas GabrielczykA Dutch-German resarch team together with Evotec SE have presented a new class of vancomycin derivatives with good safety profile that kill multi-resistant, Gram-positive bugs.
Roche inks US$2bn biobucks deal with Sangamo
/in News/by Thomas GabrielczykAfter Sangamo Therapeutics Inc. presented an epigenetic ZFN-based repressor at ASGCT 2024 that reduces the expression of the tau protein in the hippocampus by 95% in Alzheimer’s models, Roche’s US subsidiary Genentech has licensed the experimental gene therapy.
Carbios SAS to expand PET recycling portfolio to the UK
/in News/by Thomas GabrielczykFrench bioplastics recycling specialist Carbios SAS and British recycling and waste management company FCC Environment want to establish a PET biorecycling facility in the UK.
FDA approves cell therapy for solid tumours
/in News/by Thomas GabrielczykThe US Food & Drug Administration has granted accelerated approval to Adaptimmune’s Tecelra as the world’s first therapy with genetically engineered T cells to fight a solid tumour.